Literature DB >> 30180267

The effect of continuous levodopa treatment during the afternoon hours.

Ilias Thomas1, Mevludin Memedi2, Jerker Westin1, Dag Nyholm3.   

Abstract

OBJECTIVE: The aim of this retrospective study was to investigate whether patients with Parkinson's disease, who are treated with levodopa-carbidopa intestinal gel (LCIG), clinically worsen during the afternoon hours and if so, to evaluate whether this occurs in all LCIG-treated patients or in a subgroup of patients.
METHODS: Three published studies were identified and included in the analysis. All studies provided individual response data assessed on the treatment response scale (TRS), and patients were treated with continuous LCIG. Ninety-eight patients from the three studies fulfilled the criteria. t tests were performed to find differences on the TRS values between the morning and the afternoon hours, linear mixed effect models were fitted on the afternoon hours' evaluations to find trends of wearing-off, and patients were classified into three TRS categories (meaningful increase in TRS, meaningful decrease in TRS, non-meaningful increase or decrease).
RESULTS: In all three studies, significant statistical differences were found between the morning TRS values and the afternoon TRS values (P-value <=0.001 in all studies). The linear mixed effect models had significant negative coefficients for time in two studies, and 48 out of 98 patients (49%) showed a meaningful decrease in TRS during the afternoon hours.
CONCLUSION: The results from all studies were consistent, both in the proportion of patients in the three groups and in the value of TRS decrease in the afternoon hours. Based on these findings, there seems to be a group of patients with predictable "off" behavior in the later parts of the day.
© 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  Parkinson disease; diurnal motor fluctuation; infusion pumps; levodopa

Mesh:

Substances:

Year:  2018        PMID: 30180267     DOI: 10.1111/ane.13020

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  3 in total

Review 1.  Levodopa-entacapone-carbidopa intestinal gel infusion in advanced Parkinson's disease: real-world experience and practical guidance.

Authors:  Dag Nyholm; Wolfgang H Jost
Journal:  Ther Adv Neurol Disord       Date:  2022-06-26       Impact factor: 6.430

Review 2.  Why do 'OFF' periods still occur during continuous drug delivery in Parkinson's disease?

Authors:  Silvia Rota; Daniele Urso; Daniel J van Wamelen; Valentina Leta; Iro Boura; Per Odin; Alberto J Espay; Peter Jenner; K Ray Chaudhuri
Journal:  Transl Neurodegener       Date:  2022-10-13       Impact factor: 9.883

3.  Initial Experience of the Levodopa-Entacapone-Carbidopa Intestinal Gel in Clinical Practice.

Authors:  Mezin Öthman; Erik Widman; Ingela Nygren; Dag Nyholm
Journal:  J Pers Med       Date:  2021-03-31
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.